Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific affibody molecule

Cancer Research

Volumn 67, Issue 6, 2007, Pages 2773-2782

  Tolmachev, Vladimir ^a,b,c   Orlova, Anna ^a,b   Pehrson, Rikard ^a,b   Galli, Joakim ^a   Baastrup, Barbro ^a   Andersson, Karl ^b   Sandström, Mattias ^c   Rosik, Daniel ^a   Carlsson, Jörgen ^b   Lundqvist, Hans ^b   Wennborg, Anders ^a   Nilsson, Fredrik Y ^a,b,d  

^a Affibody AB   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d Affibody AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN PENTETATE LUTETIUM LU 177 PLUS EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IODINE 131; ISOTHIOCYANIC ACID DERIVATIVE; LUTETIUM 177; PERTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY TUBULE ABSORPTION; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; TUMOR GROWTH; TUMOR XENOGRAFT; URINARY EXCRETION;

ANIMALS; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOTOXINS; LUTETIUM; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; RADIOISOTOPES; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33947672248     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1630     Document Type: Article

References (50)

1. Volkert WA, Hoffman TJ. Therapeutic radiopharmaceuticals. Chem Rev 1999;99:2269-92.
2. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63.
3. Davis T. Long-term results of a randomized trial comparing tositumomab and iodine-131 Tositumomab (BEXXAR) with tositumomab alone in patients with relapsed or refractory low grade (LG) or transformed low grade (T-LG) non-Hodgkin's lymphoma (NHL). Blood 2003;102:405-6.
4. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002;43:693-713.
5. Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 2002;13: 603-8.
6. Jhanwar YS, Divgi C. Current status of therapy of solid tumors. J Nucl Med 2005;46:141-50.
7. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000;7:971-94.
8. Wikman M, Steffen AC, Gunnieriusson E, et al. Selection and characterisation of HER2/neu-binding affibody ligands. Protein Eng Des Sel 2004;17:455-62.
9. Orlova A, Magnusson M, Eriksson T, et al. Tumor imaging using a picomolar affinity HER2 binding Affibody molecule. Cancer Res 2006;66:4339-48.
10. Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren PA. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 1997;15:772-7.
11. Ronnmark J, Gronlund H, Uhlen M, Nygren PA. Human immunoglobulin A (IgA)-specific ligands from combinatorial engineering of protein A. Eur J Biochem 2002;269:2647-55.
12. Aunoble B, Sanches R, Didier E, Bignon YJ. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer [review]. Int J Oncol 2000;16: 567-76.
13. Carlsson J, Nordgren H, Sjostrom J, et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004;90:2344-8.
14. Gardmark T, Wester K, de la Torre M, Carlsson J, Malmstrom PU. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int 2005;95:982-6.
15. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
16. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-9.
17. Baxevanis CN, Sotiriadou NN, Gritzapis AD, et al. Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother 2006;55:85-95.
18. DeNardo SJ. Radioimmunodetection and therapy of breast cancer. Semin Nucl Med 2005;35:143-51.
19. Tsai SW, Sun Y, Williams LE, Raubitschek AA, Wu AM, Shively JE. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5. Bioconjug Chem 2000;11:327-34.
20. 111In labeled Herceptin. Nucl Med Biol 2002;29:599-606.
21. 177Lu]pertuzumab. Experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging 2005;32:1457-62.
22. Olafsen T, Tan GJ, Cheung CW, et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 2004;17:315-23.
23. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001;61:4750-5.
24. Steffen AC, Orlova A, Wikman M, et al. Affibody mediated tumor targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging 2006;33:631-8.
25. Mume E, Orlova A, Larsson B, et al. Evaluation of ((4-hydroxyphenyl) ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjug Chem 2005;16:1547-55.
26. Orlova A, Nilsson F, Wikman M, Ståhl S, Carlsson J, Tolmachev V. Comparative in vivo evaluation of iodine and technetium labels on anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med 2006;47:512-9.
27. 111In-benzyl- DTPA-ZHER2:342, an Affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 2006;47:846-53.
28. Peters T, Jr. Serum albumin. Adv Protein Chem 1985; 37:161-245.
29. Yeh P, Landais D, Lemaitre M, et al. Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc Natl Acad Sci U S A 1992; 89:1904-8.
30. Syed S, Schuyler PD, Kulczycky M, Sheffield WP. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood 1997;89:3243-52.
31. Osborn BL, Sekut L, Corcoran M, et al. Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur J Pharmacol 2002;456:149-58.
32. Makrides SC, Nygren PA, Andrews B, et al. Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor. J Pharmacol Exp Ther 1996;277:534-42.
33. Dennis MS, Zhang M, Meng YG, et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 2002;277:35035-43.
34. Linhult M, Binz HK, Uhlen M, Hober S. Mutational analysis of the interaction between albumin-binding domain from streptococcal protein G and human serum albumin. Protein Sci 2002;11:206-13.
35. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 2004;3:488-99.
36. Lundberg E, Höidén-Guthenberg I, Larsson B, Uhlén M, Gräslund T. Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. J Immunol Methods 2007;319:53-63.
37. Levitt DG. The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol 2003;3:3.
38. Sharkey RM, Goldenberg DM. Advances in radioimmunotherapy in the age of molecular engineering and pretargeting. Cancer Invest 2006;24:82-97.
39. Paganelli G, Magnani P, Zito F, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991;51: 5960-6.
40. Wang Z, Garkavij M, Tennvall JG, Ohlsson T, Strand SE, Sjogren HO. Application of extracorporeal immunoadsorption to reduce circulating blood radioactivity after intraperitoneal administration of indium-111-HMFG1-biotin. Cancer 2002;94:1287-92.
41. Kobayashi H, Sakahara H, Hosono M, et al. Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a "chase" without decreased accumulation in the target tumor. J Nucl Med 1994;35:1677-84.
42. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990; 31:1191-8.
43. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. Microvasc Res 1991;41:5-23.
44. Tolmachev V, Orlova A, Lundqvist H. Approaches to improvement of cellular retention of radiohalogen labels delivered by internalizing tumor targeting proteins and peptides. Curr Med Chem 2003;10: 2447-60.
45. 111In- trastuzumab (Herceptin) Fab fragments. Nucl Med Biol 2005;32:51-8.
46. Smith-Jones PM, Solit DB, Akhurst T, et al. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004;22:701-6.
47. Adams GP, Shaller CC, Dadachova E, et al. A single treatment of yttrium-90-labeled CHX-A″-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res 2004; 64:6200-6.
48. 177Lu]pertuzumab. Experimental therapy of HER-2 expressing xenografts. Cancer Res 2007;67:326-31.
49. Milenic DE, Garmestani K, Brady ED, et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 2004;10:7834-41.
50. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998;25:201-12.